The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Series C | Alive

Total Raised


Last Raised

$37M | 1 yr ago

About Heartseed

Heartseed is focused on the research and development of stem cell-based heart regeneration technology using iPS cells.

Heartseed Headquarter Location

12-9 Daikyo-cho, Shinjuku-ku Art Complex Center 302

Tokyo, 160-0015,


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Heartseed

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Heartseed is included in 4 Expert Collections, including Regenerative Medicine.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).


Medical Devices

8,442 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.


Health IT

7,900 items

Heartseed Patents

Heartseed has filed 5 patents.

The 3 most popular patent topics include:

  • Androgens and anabolic steroids
  • Biotechnology
  • Capacitors
patents chart

Application Date

Grant Date


Related Topics




Transcription factors, Stem cells, Biotechnology, Developmental biology, Cell biology


Application Date


Grant Date



Related Topics

Transcription factors, Stem cells, Biotechnology, Developmental biology, Cell biology



Latest Heartseed News

Japan’s five hottest biotech companies in healthcare

Jun 15, 2022

15/06/2022 - 6 minutes While historically lacking in foreign investments, Japan’s biotech scene is thriving with global investors showing increasing interest. Here are five of the hottest Japanese private companies innovating in the healthcare space. Japan boasts one of the highest life expectancies in the world, and, faced with a rapidly aging population , is witnessing a growing burden of chronic conditions including cardiovascular disease and type 2 diabetes. For this reason, the Japanese healthcare authorities are encouraging research into the treatment and prevention of these diseases, in addition to promoting the potential of regenerative medicine . In addition to having a roster of healthcare giants including Takeda, Astellas Pharma and Eisai, Japan is also an Asian hotspot for biotech companies. Upcoming startups have historically been limited in foreign funding and reliant on local venture capital players such as Nippon Venture Capital, Shinsei Capital Partners, and the University of Tokyo Edge Capital Partners. In 2021, however, the amount of foreign investment flowing into the Japanese biotech space rose to ​​$98 million , almost triple the haul of previous years. The most prominent global backers included Newton Biocapital, F-Prime Capital, and SoftBank Group. This trend arose as the COVID-19 pandemic triggered a wave of investor enthusiasm in biotechnology around the world. With the help of local experts, we’ve listed five of the hottest private biotech companies in Japan. These firms, shown in alphabetical order, have raised large funding rounds in the last two years and are developing innovative treatments for a range of conditions including cancer, cardiovascular disease and inflammatory disorders. Table of contents Headquarters: Fujisawa Chordia Therapeutics derives its name from the English term ‘chord’ — referring to a collection of musical notes normally played in harmony. In a similar way, the company aims to work in harmony with stakeholders and collaborators to develop first-in-class small molecule treatments for cancer. Chordia’s lead program is a drug that disrupts the processing of RNA in tumor cells. In a healthy cell, RNA molecules are typically transcribed from a DNA template and spliced together to guide the production of new proteins. Some cancer cells accumulate mutations in the RNA splicing machinery and become vulnerable to Chordia’s drugs that interfere with this process. Chordia raised $31 million (4 billion yen) in a Series C round in May 2022. The aim of the round was to push the company’s lead drug through phase I testing and fund the preclinical development of the rest of its pipeline. This month, the company announced interim results from the phase I trial of its lead candidate, with four of the recruited patients so far showing signs of responding to the treatment. Content continues below Headquarters: Tokyo Heart failure occurs when the heart muscle is irreparably damaged and is unable to pump blood. While this deadly condition can be treated with a heart transplant, there is a general shortage of donors available, making a pressing need for alternatives. In June 2021, the stem cell therapy developer Heartseed raised $36.5 million (4 billion yen) in a Series C round. The mission is to provide a regenerative route to saving the heart via stem cell therapy. In the lab, Heartseed reprograms skin cells from the patient into a type of stem cell called induced pluripotent stem cells and grows these stem cells into heart muscle cells. The company then injects the muscle cells as a small cluster, or ‘seed,’ into heart tissue to repair the muscle. The proceedings from its Series C round will allow Heartseed to take its lead candidate into clinical development, including a phase I/II trial scheduled for later this year. Last year, Heartseed also licensed its treatment to Novo Nordisk in Denmark to co-develop the treatment outside of Japan. Source: Shutterstock Headquarters: Tokyo LUCA Science hit the headlines in the last week for raising an impressive $30.3 million (3.86 billion yen) in a Series B round. The company is developing an unusual approach for treating a wide range of diseases: delivering a therapy based on mitochondria, the energy production plants in human cells. One example where the technology could work well is in strokes and heart attacks, where blood flow is blocked to critical tissue in the brain and heart respectively. The reperfusion of blood to these tissues after the blockage can kill the tissue by damaging its mitochondria. Delivering healthy mitochondria could keep the tissue working properly and protect it from harm. LUCA Science plans to use its recent Series B winnings to accelerate the preclinical development of its mitochondrial therapies and establish its manufacturing process. In May 2022, the firm also inked a collaboration deal with compatriot pharmaceutical company Kyowa Kirin Co., Ltd. to co-develop a mitochondrial therapy for rare genetic diseases. Modulus Discovery Inc. Headquarters: Boston, U.S., and Tokyo Modulus Discovery is a preclinical-stage drug discovery specialist. The company focuses on developing small molecule treatments for conditions such as cancer, inflammatory disorders and rare genetic conditions. The firm uses a mixture of strategies to speed up the drug discovery process. These include simulating target proteins using a supercomputer; structural protein biology; forming collaborations such as with the peptide drug expert PeptiDream; and tapping into global networks for biological expertise. Modulus’ most advanced drug program is in late-stage preclinical testing for the treatment of chronic inflammatory diseases. In March 2022, Modulus bagged $20.4 million (2.34 billion yen) in a Series C round. The cash is earmarked to advance the company’s R&D programs by expanding its infrastructure, collaborations and headcount. Source: Shutterstock Headquarters: Tokyo The name Noile-Immune is derived from blending together the phrases ‘no illness’ and ‘no immunity, no life.’ This company is developing CAR-T cell therapies for the treatment of cancer, which traditionally consist of extracting the patient’s immune T cells, engineering them in the lab to hunt down cancer cells, and reinfusing them into the patient. Unlike approved CAR-T cell therapies, which are limited to treating forms of blood cancer, Noile-Immune aims its therapies at treating solid tumors. The company does this by engineering immune T cells to produce proteins that cause immune cells to migrate into the tumor site. Noile-Immune is testing its lead candidate in a phase I in patients with solid tumors. The firm is also co-developing therapies with partners including Takeda and the European cell therapy specialists Adaptimmune and Autolus. Additionally, Noile-Immune has an allogeneic version of its cell therapy in the pipeline — where immune T cells are sourced from healthy donors rather than the patient. To finance the clinical development of its lead candidate, Noile-Immune raised $21.8 million (2.38 billion yen) in a Series C round in early 2021. The company hit a setback in January 2022 when a collaboration deal fell through with the U.S. player Legend Biotech. Nonetheless, other external companies remain interested in Noile-Immune’s offering, including Japan-based Daiichi Sankyo Company Ltd., which opted to assess Noile-Immune’s technology in late 2021. Cover image via Elena Resko. Thanks to feedback from Shiohara Azusa, VC Investor at The University of Tokyo Edge Capital, and Hironoshin Nomura, Chief Financial Officer, Sosei Group Corporation. Explore Related Topics:

Heartseed Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Heartseed Rank

  • When was Heartseed founded?

    Heartseed was founded in 2015.

  • Where is Heartseed's headquarters?

    Heartseed's headquarters is located at 12-9 Daikyo-cho, Shinjuku-ku, Tokyo.

  • What is Heartseed's latest funding round?

    Heartseed's latest funding round is Series C.

  • How much did Heartseed raise?

    Heartseed raised a total of $70.18M.

  • Who are the investors of Heartseed?

    Investors of Heartseed include Nissay Capital, Medipal Holdings Corporation, ITOCHU CHEMICAL FRONTIER Corporation, Sumitomo Mitsui Trust Investment, SMBC Capital and 13 more.

  • Who are Heartseed's competitors?

    Competitors of Heartseed include CUORiPS.

You May Also Like

Avery Therapeutics

Avery Therapeutics is a company that focuses on developing tissue-engineered therapeutics to treat diseases and injuries to human muscles. Its main product, MyCardia, is being developed to address and treat heart failure. It specializes in tissue engineering therapeutics, tissue engineering, regenerative medicine, cardiology, and more. It was founded in 2016 and is based in Tucson, Arizona.


CUORiPS is a developer of cell therapy products. The company develops allogeneic iPSC-derived cardiomyocyte sheets for the treatment of heart failure. It aims to enable transplantation of the sheets for patients with severe deficiencies in their heart function.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.